View larger version (50K):
[in this window]
[in a new window]
|
Figure 9. A, representative Western blot analyses demonstrating the effects of the caspase-3/7 inhibitor DEVD-fmk and the pan-caspase inhibitor zVAD-fmk on protein expression in 518A2 cells treated with G4126 or G3139 (100 nmol/L). B, inclusion of either the caspase-3/7 inhibitor DEVD-fmk (100 µmol/L) or the pan-caspase inhibitor zVAD-fmk (100 µmol/L) to oligonucleotide (100 nmol/L)/LipofectAMINE 2000 (1.9 µg/mL)–treated cells can maintain cell viability as determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay after 2 and 3 days. Columns, average (n = 3); bars, SD.
|
